Loading patent…
AssigneeGenset S.A.
InventorsDaniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux
Estimating the term…
The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.
A composition comprising an isolated and purified polynucleotide encoding a polypeptide comprising the polypeptide of SEQ ID NO:232.
A host cell recombinant for a polynucleotide encoding a polypeptide comprising the polypeptide of SEQ ID NO:232.
A host cell recombinant for a polynucleotide comprising the sequence of SEQ ID NO:19.
A host cell recombinant for a polynucleotide comprising the sequence of SEQ ID NO:25.
A recombinant vector comprising a polynucleotide encoding a polypeptide comprising the polypeptide of SEQ ID NO:232.
A recombinant vector comprising a polynucleotide comprising the sequence of SEQ ID NO:19.
A recombinant vector comprising a polynucleotide comprising the sequence of SEQ ID NO:25.
A composition in which at least about 50% of the nucleic acid in said composition exhibits a single nucleotide sequence and said single nucleotide sequence is a sequence which encodes a polypeptide comprising the polypeptide of SEQ ID NO:232.
A composition in which at least 50% by weight of the nucleic acid has a single nucleotide sequence which encodes a polypeptide comprising the polypeptide of SEQ ID NO:232.
A method of making an isolated and purified polypeptide comprising:
Dependencies are inferred from the claim text.